Journal
EMERGING MICROBES & INFECTIONS
Volume 7, Issue -, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1038/s41426-018-0161-7
Keywords
-
Categories
Funding
- French Agence Nationale de la Recherche [ANR-14-CE14-0001]
- European Virus Archive goes global project (EVAg
- European Union-Horizon 2020 programme) [653316]
- Agence Nationale de la Recherche (ANR) [ANR-14-CE14-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Zika virus (ZIKV) has recently become dispersed throughout the tropics and sub-tropics, causing epidemics associated with congenital disease and neurological complications. There is currently no commercial vaccine for ZIKV. In this study, we describe the initial development of a chimeric virus containing the prM/E proteins of a ZIKV epidemic strain incorporated into a yellow fever 17-D attenuated backbone. Using the versatile and rapid ISA (Infectious Subgenomic Amplicons) reverse genetics method, we compared different constructs and confirmed the need to modify the cleavage site between the pre-peptide and prM protein. Genotypic characterization of the chimeras indicated that the emergence of compensatory mutations in the E protein was required to restore viral replicative fitness. Using an immunocompromised mouse model, we demonstrated that mice infected with the chimeric virus produced levels of neutralizing antibodies that were close to those observed following infection with ZIKV. Furthermore, pre-immunized mice were protected against viscerotropic and neuroinvasive disease following challenge with a heterologous ZIKV strain. These data provide a sound basis for the future development of this ZIKV vaccine candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available